Objective: To summarize the clinical characteristics, therapeutic effect and prognostic factors of patients with Hodgkin's lymphoma (HL).
Methods: A total of 129 patients with HL diagnosed in Peking University Third Hospital from January 2010 to March 2021 who were given at least one efficacy assessment after treatment were enrolled, and their clinical data, including sex, age, pathological type, Ann Arbor stage, ECOG score, blood test, β2-microglobulin, lactate dehydrogenase level, albumin level were collected. The clinical characteristics, therapeutic effect and long-term prognosis of the patients were summarized and analyzed.
Results: In classical HL, nodular sclerosis HL accounted for the highest proportion of 51.6%, followed by mixed cellularity HL (36.5%), lymphocyte-rich classical HL (3.2%), and lymphocyte depletion HL (0.7%), while nodular lymphocyte predominant HL accounted for 4.8%. The 3-year overall survival (OS) rate of HL patients was 89.8%, and 5-year OS was 85.0%. The 3-year progression-free survival (PFS) rate was 73.4%, and 5-year PFS was 63.1%. Multivariate regression analysis indicated that IPI score was an independent negative factor, while hemoglobin (Hb) level was an independent positive factor for OS in HL patients. When the mediastinal mass size was 9.2 cm, it was most significant to judge the survival status of HL patients. 5-year OS and 5-year PFS were 97.4% and 76.0% in early-stage HL patients without large mass, respectively, while in patients with advanced-stage HL was 83.4% and 55.9% (both P < 0.05). After 2-4 courses of treatment, the overall response rate (ORR) of patients who received chemotherapy combined with radiotherapy was 95.0%, while that was 89.6% in those with chemotherapy alone.
Conclusions: The overall prognosis of patients with HL is satisfactory, especially those in early-stage without large mass. IPI score and Hb level are independent risk factors for the prognosis of HL patients. A 9.2 cm mediastinal mass can be used as the cut-off value for the prognosis of Chinese HL patients.
题目: 成人霍奇金淋巴瘤的单中心真实世界研究.
目的: 总结霍奇金淋巴瘤（HL）患者的临床特征、治疗效果，并分析患者的预后影响因素。.
方法: 纳入从2010年1月-2021年3月在北京大学第三医院诊断并至少进行1次疗效评估的129例HL患者，收集患者的临床资料，包括性别、年龄、病理类型、Ann Arbor分期、ECOG评分、血常规、β2-微球蛋白、乳酸脱氢酶水平、白蛋白水平等，总结分析患者的临床特征、治疗效果及远期预后。.
结果: 经典HL中结节硬化型所占比例最高为51.6%，其次为混合细胞型（36.5%）、富于淋巴细胞型（3.2%）和淋巴细胞消减型（0.7%），而结节性淋巴细胞为主的HL占4.8%。HL患者3年的总体生存率为89.8%，5年为85.0%；3年的无进展生存率为73.4%，5年为63.1%。多因素回归分析结果显示，IPI评分是HL患者预后生存的独立负性影响因素，而血红蛋白水平是独立正性影响因素。纵隔包块大小为9.2 cm时对判断HL患者的生存状态最有意义。早期无大包块HL患者5年总体生存率和无进展生存率分别为97.4%和76.0%，而晚期HL患者分别为83.4%和55.9%（均P <0.05）。治疗2-4个疗程后对患者的治疗效果进行评估，其中选择化疗联合放疗的患者总体有效率为95.0%，而单用化疗的患者为89.6%。.
结论: HL患者总体预后较好，尤其是早期非大包块HL患者。IPI评分及血红蛋白水平是影响HL患者预后的独立危险因素。纵隔包块大于9.2 cm可作为判断中国人HL患者预后的临界值。.
Keywords: Hodgkin's lymphoma; retrospective study; survival analysis.